#1 Clinical Trials Search in Europe

Utreloxastat

Utreloxastat, also known as PTC857, is a promising drug currently being studied in clinical trials for the treatment of Amyotrophic Lateral Sclerosis (ALS). This article explores the ongoing research into Utreloxastat’s potential efficacy, safety, and tolerability in adults with ALS, providing insights into the drug’s development and its possible impact on disease progression.

Table of Contents

What is UTRELOXASTAT?

UTRELOXASTAT, also known as PTC857, is a new investigational drug being developed by PTC Therapeutics, Inc. for the treatment of Amyotrophic Lateral Sclerosis (ALS)[1]. It is currently undergoing clinical trials to assess its effectiveness and safety in patients with ALS. UTRELOXASTAT is also known by other names, including EPI 857 and 2,3,5-trimethyl-6-nonyl-2,5-cyclohexadiene-1,4-dione[1].

What Medical Condition Does UTRELOXASTAT Treat?

UTRELOXASTAT is being developed to treat Amyotrophic Lateral Sclerosis (ALS)[1]. ALS is a progressive neurological disease that affects nerve cells in the brain and spinal cord, leading to loss of muscle control. It is often referred to as Lou Gehrig’s disease. ALS causes muscle weakness and atrophy throughout the body, eventually affecting a person’s ability to speak, eat, move, and breathe.

How Does UTRELOXASTAT Work?

While the exact mechanism of action of UTRELOXASTAT is not explicitly stated in the provided information, it is being studied for its potential to reduce disease progression in ALS patients[1]. The drug is being investigated for its effects on various aspects of ALS, including:

  • Slowing down the progression of the disease
  • Improving respiratory function
  • Enhancing motor/limb and bulbar function (which affects speech and swallowing)
  • Potentially improving survival rates
  • Improving quality of life for ALS patients

Current Clinical Trial Information

UTRELOXASTAT is currently being studied in a Phase 2 clinical trial called CARDINALS (PTC857-CNS-001-ALS)[1]. This trial is designed to assess the efficacy, safety, tolerability, pharmacokinetics (how the drug moves through the body), and biomarker effects of PTC857 in adult subjects with ALS. The study is structured in three parts:

  1. Treatment Period (Part A): Participants are randomly assigned to receive either UTRELOXASTAT (250 mg twice daily) or a matching placebo for 24 weeks[1].
  2. Long-Term Extension Period (Part B): Participants continue treatment for an additional 28 weeks, with all subjects receiving open-label UTRELOXASTAT[1].
  3. Continued Long-Term Extension Period (Part C): Participants can continue treatment for an additional 108 weeks, receiving open-label UTRELOXASTAT[1].

Dosage and Administration

In the clinical trial, UTRELOXASTAT is being administered as an oral solution at a dose of 250 mg twice daily[1]. The maximum daily dose being studied is 500 mg. It’s important to note that this dosage is specific to the clinical trial and may change based on the results of the study.

Who Can Participate in the Clinical Trial?

The clinical trial has specific eligibility criteria for participants. Some key inclusion criteria include:

  • Adults aged 18-80 years
  • Diagnosed with ALS within the past 24 months
  • Have a total ALS Functional Rating Scale-Revised (ALSFRS-R) score of at least 34
  • Have relatively preserved respiratory function

There are also several exclusion criteria, such as pregnancy, certain medical conditions, and use of specific medications[1].

Potential Benefits of UTRELOXASTAT

While the effectiveness of UTRELOXASTAT is still being studied, the clinical trial aims to evaluate several potential benefits:

  • Reduction in disease progression
  • Improvement in respiratory function
  • Enhancement of motor/limb and bulbar function
  • Potential increase in survival rates
  • Improvement in quality of life
  • Reduction in plasma neurofilament light chain (NfL) activity, a biomarker of neuronal damage[1]

Safety Considerations

As with any investigational drug, the safety of UTRELOXASTAT is being closely monitored in the clinical trial. The study is assessing:

  • The number and severity of treatment-emergent adverse events
  • Changes in clinical laboratory tests
  • Physical examination results
  • Vital signs
  • Suicide risk (using the Columbia-Suicide Severity Rating Scale)
  • Electrocardiogram (ECG) results[1]

It’s important to note that as an investigational drug, UTRELOXASTAT is not yet approved for general use, and its safety and efficacy are still being evaluated. Patients interested in this treatment should consult with their healthcare providers about the possibility of participating in clinical trials or other treatment options for ALS.

Aspect Details
Drug Name Utreloxastat (PTC857)
Condition Studied Amyotrophic Lateral Sclerosis (ALS)
Trial Phase Phase 2
Study Design Randomized, Double-Blind, Placebo-Controlled
Primary Objective Evaluate efficacy in reducing ALS disease progression
Dosage 250 mg twice daily (oral solution)
Trial Duration Up to 160 weeks (including extension periods)
Key Assessments ALSFRS-R, survival, respiratory function, motor function, quality of life
Biomarker Plasma neurofilament light chain (NfL)

FAQ

  • What is Utreloxastat and what is it being studied for? Utreloxastat, also known as PTC857, is a drug being investigated as a potential treatment for Amyotrophic Lateral Sclerosis (ALS). It is currently undergoing clinical trials to assess its effectiveness in slowing down the progression of ALS in adult patients.
  • What phase of clinical trials is Utreloxastat currently in? Utreloxastat is currently in Phase 2 clinical trials. This phase involves a randomized, double-blind, placebo-controlled study to evaluate the drug's efficacy, safety, and tolerability in adults with ALS.
  • How is the Utreloxastat clinical trial structured? The trial is divided into three parts: Part A (Treatment Period), Part B (Long-Term Extension Period), and Part C (Continued Long-Term Extension Period). Participants are initially randomized to receive either Utreloxastat or a placebo, with later parts of the study offering open-label Utreloxastat treatment to all participants.
  • What are the main objectives of the Utreloxastat clinical trial? The primary objective is to evaluate Utreloxastat's efficacy in reducing ALS disease progression. Secondary objectives include assessing its safety and tolerability, effects on respiratory and motor function, survival rates, quality of life improvements, and changes in certain biomarkers associated with ALS.
  • How is Utreloxastat administered in the clinical trial? Utreloxastat is administered as an oral solution. In the trial, participants receive either 250 mg twice daily (BID) of Utreloxastat or a matching placebo. The dosage remains consistent throughout the different phases of the study.

Ongoing Clinical Trials on Utreloxastat

  • Study of utreloxastat (PTC857) in adults with Amyotrophic Lateral Sclerosis (ALS) to evaluate its effectiveness in slowing disease progression

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Germany Ireland Italy +5

Glossary

  • Amyotrophic Lateral Sclerosis (ALS): A progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing loss of muscle control.
  • Utreloxastat (PTC857): An investigational drug being studied for the treatment of ALS, also known by its product code PTC857.
  • ALSFRS-R: ALS Functional Rating Scale-Revised, a tool used to measure the functional status of ALS patients.
  • Placebo: A substance with no active therapeutic effect, used as a control in testing new drugs.
  • Double-blind: A study design where neither the participants nor the researchers know who is receiving the actual treatment or placebo.
  • Randomized: Participants are assigned to treatment groups by chance, reducing bias in the study.
  • Efficacy: The ability of a treatment to produce a desired effect.
  • Biomarker: A measurable indicator of a biological state or condition, used to track disease progression or treatment effects.
  • Neurofilament light chain (NfL): A protein released when neurons are damaged, used as a biomarker in ALS research.
  • Open-label: A type of clinical trial where both researchers and participants know which treatment is being administered.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-ptc857-for-adults-with-amyotrophic-lateral-sclerosis-als/